High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse

Journal of Neuroimmunology

Volumn 176, Issue 1-2, 2006, Pages 134-140

  Mirowska Guzel, Dagmara M ^a,c   Kurowska, Katarzyna ^a   Skierski, Janusz ^b   Koronkiewicz, Mirosława ^b   Wicha, Wojciech ^a   Kruszewska, Jadwiga ^a   Czlonkowski, Andrzej ^c   Czlonkowska, Anna ^a,c  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Interleukin 8; Intravenous methylprednisolone; Multiple sclerosis; Peripheral blood immune profile; Relapse

Indexed keywords

CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 8; METHYLPREDNISOLONE;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG EFFECT; DRUG MEGADOSE; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; STATISTICAL SIGNIFICANCE;

ADULT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; KILLER CELLS, NATURAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS;

EID: 33746063224     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.03.024     Document Type: Article

References (37)

1. Abruzzo L.V., and Rowley D.A. Homeostasis of the antibody response: immunoregulation by NK cells. Science 222 (1983) 581-585
2. Airla N., Luomal M., Elovaara I., Kettunen E., Knuutila S., and Lehtigmaki T. Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. J. Neurol. 251 (2004) 1215-1219
3. Arnason B.G.W., Dayla A., Qu Z.X., Jensen M.A., Genc K., and Reder A.T. Mechanism of action of interferone-beta in multiple sclerosis. Springer Semin. Immunopathol. 18 (1996) 125-148
4. Baggiolini M., Dewald B., and Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55 (1994) 97-179
5. Baggiolini M., Loetscher P., and Moser B. Interleukin-8 and the chemokine family. Int. J. Immunopharmacol. 17 (1995) 103-108
6. Balasingham V., Tejada-Berges T., Wright E., Bouckova R., and Yong W. Reactive astrogliosis in neonatal mouse brain and its modulation by cytokines. J. Neurosci. 14 (1994) 846-856
7. Burgener I., Van Ham L., Jaggy A., Vandevelde M., and Tipold A. Chemotactic activity and IL-8 levels in the cerebrospinal fluid in canine steroid responsive meningitis-arteritis. J. Neuroimmunol. 89 (1998) 182-189
8. Casilli F., Bianchini A., Gloaguen I., Biordi L., Alesse E., Festuccia C., Cavalieri B., Strippoli R., Cervellera M.N., Di Bitondo R., Ferretti E., Mainiero F., Bizzarri C., Colotta F., and Bertini R. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemikine receptors CXCR1 and CXCR2. Biochem. Pharmacol. 69 (2005) 385-394
9. Cassatella M.A. The production of cytokies by polymorhonuclear neutrophils. Immunol. Today 16 (1995) 21-26
10. Cross A.H., Trotter J.L., and Lyons A. B cells and antibodies in the CNS demyelinating disease. J. Neuroimmunol. 112 (2001) 1-14
11. Ehrlich L.C., Hu S., Sheng W.S., Sutton R.L., Rockswold G.L., Peterson Ph.K., and Chao Ch.C. Cytokine regulation of human microglial cell IL-8 production. J. Immunol. 160 (1998) 1944-1948
12. El Behi M., Dubucquoi S., Lefranc D., Zéphir H., De Seze J., Vermersch P., and Prin L. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 96 (2005) 11-26
13. Fattori E., Lazzaro D., Musiani P., Modesti A., Alonzi T., and Cilberto G. IL-6 expression in neurons of transgenic mice causes reactive astrogliosis and increase in remified microglial cells but no neuronal damage. Eur. J. Neurosci. 7 (1995) 2441-2449
14. Genain C.P., Cannella B., Hauser S.L., and Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5 (1999) 170-175
15. Gerriste K., Deen C., Fasbender M., Ravid R., Boersma W., and Claassen E. The involvement of specific anti-myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J. Neuroimmunol. 49 (1994) 153-159
16. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone Jr. M.A., Luster A.D., Luscinskas F.W., and Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999) 718-723
17. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., and van den Noort S. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 58 (2002) 169-178
18. Hartung H.P., and Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107 (2000) 140-147
19. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajiama K., Koyama K., Iwamatsu A., Tsunasawa S., Sakiyama F., Matsui H., Takahara Y., Taniguchi T., and Kishimito T. Complementary DNA for a novel human interleukin (BSF-2) that induce B lymphocytes to produce immunoglobulin. Nature 324 (1986) 73-76
20. Holmes W.E., Lee J., Kuang W.J., Rice G.C., and Wood W.I. Structure and functional expression of a human interleukin-8 receptor. Science 253 (1991) 1278-1280
21. Jablonska E., Jablonski J., and Holownia A. Role of neutrophils in release of some cytokines and their soluble receptors. Immunol. Lett. 70 (1999) 191-197
22. Kouwenhoven M., Teleshova N., Ozenci V., Press R., and Link H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J. Neuroimmunol. 112 (2001) 197-205
23. Kupersmith M.J., Kaufman D.O., Paty D.W., Ebers G., McFarland H., Johnson K., Reingold S., and Whitaker J. Megadose corticosteroids in multiple sclerosis. Neurology 44 (1994) 1-4
24. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 33 (1983) 1444-1452
25. Li A., Dubey S., Varney M.L., Dave B.J., and Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170 (2003) 2276-3369
26. Lund B.T., Ashikian N., Ta H.Q., Chakryan Y., Manoukian K., Groshen S., Gilmore W., Cheema G.S., Stohl W., Burnett M.E., Ko D., Kachuck N.J., and Weiner L.P. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 155 (2004) 161-171
27. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
28. Melani C., Mattia G.F., Silvani A., Care A., Rivoltini L., Permiani G., and Colombo M.P. Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. Blood 81 (1993) 2744-2749
29. Milligan N.M., Newcombe R., and Compston D.A.S. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50 (1987) 511-516
30. Mirowska D., Skierski J., Paz A., Koronkiewicz M., Zaborski J., Kruszewska J., Czlonkowski A., and Czlonkowska A. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-β-1a treatment in multiple sclerosis patients. J. Neurol. 250 (2003) 1229-1236
31. Olivieri R.L., Valentino P., Russo C., and Sibilia G. Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study. Neurology 50 (1998) 1833-1836
32. Omari K.M., John G.R., Sealfon S.C., and Raine C.S. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 128 (2005) 1003-1015
33. Pozzilli C., Marinelli F., Romano S., and Bagnato F. Corticosteroids treatment. J. Neurol. Sci. 223 (2004) 47-51
34. Schrönrock L.M., Gawlowski G., and Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci. Lett. 294 (2000) 45-48
35. Schulte-Herbrüggen O., Nassenstein Ch., Lommatzsch M., Quarcoo D., Renz H., and Braun A. Tumor necrosis factor-α and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 160 (2005) 204-209
36. Wang H.Y., Matsui M., Araya S., Onai N., Matsushima K., and Saida T. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 216 (2003) 61-66
37. Xing L., and Remick D.G. Neutrophils as firemen, production of anti-inflammatory mediators by neutrophils in a mixed cell environment. Cell. Immunol. 231 (2004) 126-132